Dynavax’s New Shingles Vaccine Candidate Shows Strong Results Against Shingrix

The shingles vaccine market has long been dominated by a single product: Shingrix. But Dynavax Technologies is looking to change that. The company just reported positive topline data from Part 1 of its Phase 1/2 clinical trial for Z-1018, a novel shingles vaccine candidate designed to rival – and potentially outperform – the current standard of care.

Key Takeaways from the Study

• Head-to-head comparison: Z-1018 was tested directly against Shingrix in adults aged 50–69.
• Immune response: Z-1018 showed antibody and T-cell responses on par with Shingrix.
  - 100% antibody response rate vs. 96.9% with Shingrix
  - 89.7% T-cell response vs. 93.5% with Shingrix
  - Composite immune response: essentially equivalent between both vaccines.
• Tolerability advantage: Participants reported fewer side effects with Z-1018.
  - Local reactions (pain, redness, swelling): 12.5% with Z-1018 vs. 52.6% with Shingrix
  - Systemic reactions (fever, fatigue, aches): 27.5% with Z-1018 vs. 63.2% with Shingrix

Why This Matters

Shingles is a painful condition caused by the reactivation of the chickenpox virus. It affects 1 in 3 people in their lifetime and risk rises sharply with age. Shingrix has been the go-to solution, but it is also known for its high reactogenicity (strong side effects), which discourages some patients from completing the two-dose schedule.

Dynavax is betting that Z-1018, with comparable protection and a more favorable tolerability profile, could open the door for broader vaccination uptake.

What’s Next for Z-1018?

Dynavax has selected its lead formulation – a 100 mcg dose with CpG 1018 plus alum adjuvant, given on an 8-week schedule – to move forward.

• Part 2 of the trial will enroll adults aged 70 and older, a group at highest risk for shingles.
• This phase will generate proof-of-concept data and further de-risk the program before a pivotal Phase 3 trial.
• If successful, Dynavax could bring a best-in-class shingles vaccine to a multi-billion-dollar market currently dominated by one player.

The Bigger Picture

Dynavax is already known for HEPLISAV-B, its hepatitis B vaccine, and its proprietary CpG 1018 adjuvant, used in multiple vaccines worldwide. With Z-1018, the company is aiming to replicate that success in another high-value market.

“We met our goal for this study. Z-1018 shows immune responses comparable to Shingrix, with fewer side effects,” said Ryan Spencer, CEO of Dynavax. “This positions us to advance into older populations and, ultimately, late-stage development.”

Bottom Line

Dynavax’s Z-1018 could emerge as a serious challenger to Shingrix, offering patients the same protection with a smoother experience. If Part 2 confirms these findings in older adults, the race for shingles vaccine dominance may finally have a new contender.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!